LAUSR

OBJECTIVE The microbiome plays an important role in a wide variety of skin disorders. Hence, dysbiosis in the skin and/or gut microbiome is associated with an altered immune response, promoting the development of skin diseases, such as atopic dermatitis, psoriasis, acne vulgaris and dandruff. Studies have shown that paraprobiotics may be promising for the treatment of skin disorders through microbiota modulation and immunomodulation. So, the objective is develop an anti-dandruff formulation using a paraprobiotic (Neoimuno LACT GB®) as active ingredient. METHODS Randomized, double-blind, placebo-controlled clinical trial was performed in patients who had any degree of dandruff. A total of 33 volunteers were recruited and randomly divided into two groups: Placebo or Treated. (1% Neoimuno LACT GB®). The ingredient used was Neoimuno LACT GB® (Bifidobacterium lactis strain CCT 7858). Combability analysis and perception questionnaire were applied before and after treatment. Statistical analyses were performed. RESULTS No adverse effects were reported by patients throughout the study. Through the combability analysis, a significant decrease in the number of particles was verified after 28 days of shampoo use. Regarding perception, there was a significant difference for the cleaning variables and improvement of the general appearance 28 days after the intervention. There were no significant differences for the itching and scaling parameters, as well as the perception parameters at 14 days. DISCUSSION Topical application of the paraprobiotic shampoo containing 1% Neoimuno LACT GB® was able to significantly improve the feeling of cleanliness and general aspects of dandruff, in addition to reducing scalp flakiness. Thus, with the results obtained through the clinical trial, Neoimuno LACT GB® presents itself as a natural, safe and effective ingredient in the treatment of dandruff. The efficacy of Neoimuno LACT GB® in dandruff was visible within 4 weeks.